Network Meta-Analysis with Competing Risk Outcomes

被引:47
作者
Ades, A. E. [1 ]
Mavranezouli, Ifigeneia [2 ]
Dias, Sofia [1 ]
Welton, Nicky J. [1 ]
Whittington, Craig [2 ]
Kendall, Tim [3 ]
机构
[1] Univ Bristol, Dept Community Based Med, Bristol BS6 6RT, Avon, England
[2] UCL, Natl Collaborating Ctr Mental Hlth, Ctr Outcomes Res & Effectiveness, Res Dept Clin Educ & Hlth Psychol, London, England
[3] Royal Coll Psychiatrists, Res & Training Unit, Natl Collaborating Ctr Mental Hlth, London SW1X 8PG, England
基金
英国医学研究理事会;
关键词
antipsychotic medication; Markov model; meta-analysis; mixed treatment comparisons; schizophrenia; MIXED TREATMENT COMPARISONS; MULTIPLE OUTCOMES; TRIALS; MODEL;
D O I
10.1111/j.1524-4733.2010.00784.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Cost-effectiveness analysis often requires information on the effectiveness of interventions on multiple outcomes, and commonly these take the form of competing risks. Nevertheless, methods for synthesis of randomized controlled trials with competing risk outcomes are limited. Objective: The aim of this study was to develop and illustrate flexible evidence synthesis methods for trials reporting competing risk results, which allow for studies with different follow-up times, and that take account of the statistical dependencies between outcomes, regardless of the number of outcomes and treatments. Methods: We propose a competing risk meta-analysis based on hazards, rather than probabilities, estimated in a Bayesian Markov chain Monte Carlo (MCMC) framework using WinBUGS software. Our approach builds on existing work on mixed treatment comparison (network) meta-analysis, which can be applied to any number of treatments, and any number of competing outcomes, and to data sets with varying follow-up times. We show how a fixed effect model can be estimated, and two random treatment effect models with alternative structures for between-trial variation. We suggest methods for choosing between these alternative models. Results: We illustrate the methods by applying them to a data set involving 17 trials comparing nine antipsychotic treatments for schizophrenia including placebo, on three competing outcomes: relapse, discontinuation because of intolerable side effects, and discontinuation for other reasons. Conclusions: Bayesian MCMC provides a flexible framework for synthesis of competing risk outcomes with multiple treatments, particularly suitable for embedding within probabilistic cost-effectiveness analysis.
引用
收藏
页码:976 / 983
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 1984, Analysis of survival data
[2]  
[Anonymous], NICE GUID COR INT TR
[3]  
[Anonymous], 1995, Markov Chain Monte Carlo in Practice
[4]  
Berkey CS, 1996, STAT MED, V15, P537, DOI 10.1002/(SICI)1097-0258(19960315)15:5<537::AID-SIM176>3.0.CO
[5]  
2-S
[6]  
Berkey CS, 1998, STAT MED, V17, P2537, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2537::AID-SIM953>3.0.CO
[7]  
2-C
[8]   Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events [J].
Bradburn, Michael J. ;
Deeks, Jonathan J. ;
Berlin, Jesse A. ;
Localio, A. Russell .
STATISTICS IN MEDICINE, 2007, 26 (01) :53-77
[9]   General methods for monitoring convergence of iterative simulations [J].
Brooks, SP ;
Gelman, A .
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 1998, 7 (04) :434-455
[10]   Simultaneous comparison of multiple treatments: combining direct and indirect evidence [J].
Caldwell, DM ;
Ades, AE ;
Higgins, JPT .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7521) :897-900